How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

KardiaMobile for detecting atrial fibrillation

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 KardiaMobile shows promise for improved detection of atrial fibrillation and atrial fibrillation recurrence. However, there is not enough good-quality economic evidence to support the case for routine adoption in the NHS.

1.2 Research is recommended to address uncertainties about the cost impact of KardiaMobile for detecting atrial fibrillation and atrial fibrillation recurrence.

Find out details of required outcomes in further research.

Why the committee made these recommendations

KardiaMobile is an electrocardiogram (ECG)-monitoring device used to detect atrial fibrillation (AF). It comprises an ECG device, a software algorithm (KardiaMobile app) that analyses the ECG data and provides a classification of rhythm including normal, possible AF, tachycardia, bradycardia or unclassified.

Clinical evidence shows that more people had their AF detected using the KardiaMobile single-lead device compared with standard care, which usually involves wearing a continuous ECG monitor such as a 24‑hour Holter monitor.

Evidence suggests that using KardiaMobile is likely to be cost saving or cost neutral for detecting atrial fibrillation and atrial fibrillation recurrence. But further economic modelling is needed to address uncertainties and to help understand the cost impact of KardiaMobile compared with standard care. This model should focus on people presenting with palpitations and people who need to monitor AF recurrence where the evidence base for using the device is strongest.